Your browser doesn't support javascript.
loading
FDA Approval Summary: Belzutifan for VHL Disease Tumors-Response.
Fallah, Jaleh; Weinstock, Chana; Mehta, Gautam U; Brave, Michael H; Pierce, William F; Pazdur, Richard; Nair, Abhilasha; Suzman, Daniel L; Amiri-Kordestani, Laleh.
Afiliação
  • Fallah J; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Weinstock C; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Mehta GU; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Brave MH; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Pierce WF; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Pazdur R; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Nair A; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Suzman DL; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Amiri-Kordestani L; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
Clin Cancer Res ; 29(3): 685, 2023 02 01.
Article em En | MEDLINE | ID: mdl-36722139
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína Supressora de Tumor Von Hippel-Lindau Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína Supressora de Tumor Von Hippel-Lindau Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article